Centessa Q2 net loss widens to $43.8M; cash $294.8M; ORX750 data expected 2H 2024

Centessa Pharmaceuticals plc

2024-Q2 EPS reported -$0.78

Net loss $43.8M vs $24.9M YoY; prior Q2 included $24.1M tax benefit.
Cash $294.8M; funds operations into mid-2026; raised $107.3M net in public offering.
ORX750 Phase 1 initiated; PoC data in sleep-deprived volunteers expected 2H 2024 using MWT.
ORX142 nominated as development candidate; IND-enabling activities underway.
SerpinPC registrational program progressing; PRESent-2 Part 1 interim analysis planned 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.